The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Malignant melanomas exhibited moderate to strong membranous and cytoplasmic positivity. Weak to moderate cytoplasmic and occasional membranous positivity was observed in breast, prostate, gastric cancer along with several colorectal, ovarian, skin and pancreatic cancers. Other malignancies were mainly negative.
Many papillary adenocarcinomas of thyroid along with a few hepatocellular carcinomas, malignant melanomas, lung and ovarian cancers displayed moderate cytoplasmic positivity. Remaining malignant cells were weakly stained or negative.
Majority of the cancers tissues exhibited weak to moderate cytoplasmic immunoreactivity, often seen with a granular pattern.
Validation
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
The multi-targeting antibody yielding a staining pattern partly consistent with characterization data for at least one of the genes whereas any of the other genes has no available gene/protein characterization data or is contradicted by gene/protein chara
Two (or more) antibodies yielding similar or partly similar staining patterns which are partly consistent with or contradicted by limited gene/protein characterization data
